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Abstract
Cocaine- and amphetamine-regulated transcript (CART) peptide was dis-
covered in the treatment of cocaine and amphetamine addiction in rats 
and received its name from this relationship. The functional role of CART 
peptide is strongly associated with feeding behaviors, and reward and 
reinforcement. Recently, a number of studies have shown that mesolimbic 
and nigrostriatal dopaminergic neuronal activities are also under the reg-
ulation of CART peptide. In this mini-review, we will introduce the current 
knowledge on the neuroanatomical, neurochemical and behavioral aspects 
of interactions of CART peptide with the mesolimbic and nigrostriatal dopa-
mine pathways. Overall, it is clear that there are functional interactions 
among CART peptide, dopamine, and psychostimulants. The next step is 
to clarify the receptor(s) and mechanisms of CART peptide to develop 
potential therapeutic drugs. [Tzu Chi Med J 2008;20(4):248–252]
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1. Introduction
In 1981, Spiess et al reported a previously unknown 
sequence of peptide that was extracted from ovine 
hypothalamus [1]. At that time, they did not know the 
physiologic function or the exact localization of this 
novel peptide. Fifteen years later, Douglass et al used 
differential display techniques and found that an mRNA 
transcript was elevated by acute administration of co-
caine and amphetamine into rat striatum [2], but two 
other studies [3,4] could not reproduce their work. The 
peptide following mRNA transcript coding was named 
cocaine- and amphetamine-regulated transcript (CART) 
peptide. CART peptide is a well-identified neurotrans-
mitter. It is produced by neurons [1], and packaged 
in vesicles [5]. Michael Kuhar’s laboratory has shown 
that CART peptide affects the downstream ERK pathway 
of G protein-coupled receptors [6,7]. The next steps 
in identifying the CART peptide as the real neurotrans-
mitter would be discoveries of CART receptor(s) and 
understanding the clearance mechanism(s). Recently, 
Jones and Kuhar, using primary neuronal cell culture, 
showed that the CART peptide receptor is a G protein-
coupled receptor [8]. Although there remains con-
troversy about whether CART peptide or its mRNA 
expression is related to drug abuse, there is no doubt 
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that CART peptides are involved in reward and rein-
forcement, feeding and satiety, stress, endocrine reg-
ulation, sensory processing and other physiological 
processes [3,9–12]. The physiological role of CART 
peptide in the nucleus accumbens and striatum is still 
unclear, however, although recent studies have shown 
that CART peptide may play a regulatory role in the 
mesolimbic and nigrostriatal dopamine systems.
2. Anatomical point of view
High densities of CART immunoreactivity are found 
in the nucleus accumbens, striatum and various hy-
pothalamic regions of rats and monkeys, and a large 
number of varicose terminals with CART immunore-
activity are located throughout the nucleus accumbens 
and form axodendritic synapses; ultrastructural ob-
servations further revealed CART immunoreactivity in 
dense varicosities and many interspersing perikarya 
[2,13–19]. In addition, electron microscopy showed 
that tyrosine hydroxylase (the rate limited enzyme of 
catecholamines)-containing nerve terminals synapse 
on CART-containing neurons in the nucleus accum-
bens [13]. The major midbrain dopaminergic systems 
can be divided into three major categories. These 
dopaminergic neurons are the long projections link-
ing the ventral tegmental area and substantia nigra 
neurons with three principal sets of targets, which 
are the nucleus accumbens, prefrontal cortex, and 
striatum. These three groups have frequently been 
termed the mesolimbic, mesocortical, and nigrostri-
atal dopaminergic systems, respectively, and play 
different physiological roles in the central nervous 
system. For instance, the nigrostriatal dopamine sys-
tem plays an important role in the regulation of the 
extrapyramidal motor system, and the mesocortical 
and mesolimbic dopamine systems are associated 
with the regulation of reinforcement, reward, and in-
centive motivation. Therefore, it has been speculated 
that CART peptide plays regulatory roles in the mes-
olimbic and nigrostriatal dopaminergic systems.
CART immunoreactive cell bodies are found in the 
nucleus accumbens and these neurons project to the 
substantia nigra, suggesting that CART peptides pro-
vide a significant modulation of a primary output cen-
ter of the basal ganglia [14,18]. The substantia nigra 
contains two anatomical divisions: the substantia nigra 
pars reticulata, which contains basal ganglia output 
GABAergic neurons; and the substantia nigra com-
pacta, which contains dopamine neurons that project 
to the striatum forming the nigrostriatal dopaminer-
gic system. In the rat, CART immunoreactive axons 
and terminals are found throughout the entire ven-
tral midbrain, but neither the ventral tegmental area 
nor the substantia nigra contains CART immunoreac-
tive cell bodies or CART mRNA, suggesting extrinsic 
sources of CART-containing innervation to these re-
gions [15,16]. Surprisingly, less than half of CART-
containing terminals in the ventral tegmental area 
form synapses with dopaminergic neurons in the rat 
[20]. The greater part of CART-containing terminals 
have contact with non-dopaminergic neurons [20]. 
Similarly, in the substantia nigra, only one fifth of 
CART-containing terminals form synapses with the 
dendritic processes and cell bodies of dopaminergic 
neurons [14,20]. In common, the majority of CART-
containing terminals in both the ventral tegmental 
area and substantia nigra do not have contact with 
the dopaminergic systems, but are apposed with the 
GABAergic neurons. Therefore, it was hypothesized that 
the effects of CART peptide on the midbrain dopami-
nergic systems may be through direct and indirect 
pathways. The direct mechanism of CART peptide on 
mesolimbic and nigrostriatal dopaminergic neuronal 
activities could be through direct stimulation of dopa-
minergic neurons. In contrast, the indirect influence 
of CART peptide on the neuronal activities of the 
mesolimbic and nigrostriatal dopaminergic systems 
could be through inhibition of GABAergic neuronal 
activity, followed by similar stimulating effects in the 
dopaminergic systems.
3. Neurochemical and behavioral points 
of view
Kimmel et al [21] found that direct administration of 
CART peptide into the ventral tegmental area pro-
duced significant psychomotor stimulant-like effects, 
including increases in locomotor activity and condi-
tioned place preference. After this study, others re-
ported the effects of CART peptide on the central 
dopaminergic systems, especially midbrain mesolim-
bic and nigrostriatal dopaminergic neuronal activities 
[22–25]. In fact, most of these studies provide indi-
rect evidence, or focus on behavioral responses fol-
lowing CART peptide treatments. Shieh [24] reported 
that dopamine turnover in the nucleus accumbens 
and striatum was elevated 15 minutes after central 
administration of CART peptide. However, only dopa-
mine turnover in the nucleus accumbens was increased 
45 minutes following CART peptide treatment, while 
that in the striatum was not. Using the ratio of the 
major dopamine metabolite (3,4-dihydroxyphenylacetic 
acid [DOPAC]) to dopamine as an index of dopamin-
ergic neuronal activity showed a similar trend (Fig. 1). 
Using microdialysis, Yang et al [25] also found that the 
major dopamine metabolites in the nucleus accum-
bens of conscious rats were significantly elevated after 
central injection of CART peptide. Interestingly, these 
stimulating effects of CART peptide on the dopamine 
turnover of the mesolimbic and nigrostriatal systems 
are influenced by the gonadal hormones, including 
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testosterone and estradiol. For instance, intracerebro-
ventricular administration of CART peptide increased 
dopamine turnover in the nucleus accumbens and 
striatum in male rats [26,27]. Stimulation of dopamine 
turnover in the nucleus accumbens and striatum by 
CART peptide was found in intact male rats, but not 
in castrated male rats [27]. This stimulation was re-
stored in castrated male rats by testosterone or dihy-
drotestosterone priming. These restoring effects were 
blocked by a testosterone antagonist, but not by an 
estradiol antagonist [27]. Moreover, similar stimula-
tion by CART peptide on the dopamine turnover of 
the mesolimbic and nigrostriatal systems in female 
rats was also influenced by estradiol [28]. Stimulation 
of nucleus accumbens and striatum dopa mine turn-
over by CART peptide was found in ovariectomized 
female rats after estradiol priming, but not in ovariec-
tomized female rats without priming. Therefore, the 
gonadal hormones, testosterone and estradiol, play 
regulatory roles in stimulation of CART peptide in the 
mesolimbic and nigrostriatal dopaminergic systems.
On the other hand, mesocortical dopaminergic neu-
ronal activity was not affected by CART peptide. For 
example, the dopamine turnover of the medial pre-
frontal cortex showed no changes at 15 and 45 min-
utes (Fig. 1), and this is similar to previous studies 
[24–28]. Previous anatomical evidence has shown 
that a high density of CART peptide exists in the nu-
cleus accumbens and striatum, the major projection 
sites of the mesolimbic and nigrostriatal dopaminer-
gic systems [13,14,17]. In contrast, low-to-extremely 
low levels of CART peptide immunoreactive fibers 
and CART mRNA were found in the medial prefrontal 
cortex, the major projection site of the mesocortical 
dopaminergic system, in both humans and rats [17,
29,30]. Taken together, these reports indicate that 
CART peptide may also act as a psychostimulant or at 
least plays a stimulatory role on the mesolimbic and 
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Fig. 1 — Dopamine turnover in the: (A) nucleus accumbens (NA); (B) striatum (ST); and (C) medial prefrontal cortex 
(MPFC) in male rats following central injection of cocaine- and amphetamine-regulated transcript (CART) peptide as 
measured by using the DOPAC/DA ratio. CART peptide (1 mg) was given in the morning, and the rats were decapitated 
15, 45 or 90 minutes later. Detailed information on the materials and methods has been reported in previous studies 
[24–28,31]. The vertical line above each bar represents the standard error of the mean (n = 6). *p < 0.05 compared with 
the DOPAC/DA ratio in saline-treated controls (white bar).
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nigrostriatal, but not the mesocortical dopaminergic 
systems.
4. Conclusion
Neuroanatomical, neurochemical and behavioral evi-
dence has shown close relationships between CART 
peptide and the mesolimbic and nigrostriatal dopa-
minergic systems. Although studies have also reported 
that CART peptide might play a regulatory role on 
other dopaminergic systems, such as the hypothalamic 
tuberoinfundibular dopamine system [24,26,31], fur-
ther data are still needed. Taken together, the role 
for CART peptide involved in modulating the reward 
and reinforcing effects of psychostimulants, feeding 
behavior and central dopaminergic systems is clearer. 
There is a great potential for CART as a therapeutic 
target for the treatment of eating disorders and psy-
chostimulant addiction. In the past, the major chal-
lenge in studies of CART peptide was the absence of 
a particular CART receptor; however, it is expected 
that the recent discovery of a CART peptide receptor 
[8] might greatly facilitate the development of useful 
agonist(s)/antagonist(s) of CART peptide for future 
therapeutic purposes.
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